Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fruquintinib Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: a Phase II Study

NCT06427005 is registered in ClinicalTrials.gov with Meng Qiu as lead sponsor.

NCT NCT06427005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06427005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fruquintinib Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: a Phase II Study
Lead sponsor
Meng Qiu
Phase
Phase 2
Overall status
Unknown status
Start date
February 20, 2023
Completion date
April 30, 2026
Enrollment
66 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fruquintinib, raltitrexed, s-1